Valneva (NASDAQ:VALN) Raised to Sell at Wall Street Zen

Valneva (NASDAQ:VALN) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Monday.

Several other analysts have also issued reports on the company. Guggenheim set a $11.00 target price on Valneva in a report on Thursday, April 16th. The Goldman Sachs Group lowered Valneva from a “neutral” rating to a “sell” rating and set a $4.90 target price on the stock. in a report on Wednesday, April 22nd. Three equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $11.98.

Valneva Stock Performance

VALN opened at $6.25 on Monday. The firm has a market cap of $593.06 million, a P/E ratio of -3.34 and a beta of 1.75. Valneva has a 52-week low of $5.06 and a 52-week high of $12.25. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.60 and a current ratio of 2.14. The business’s fifty day moving average is $6.12 and its 200-day moving average is $8.37.

Valneva (NASDAQ:VALN) last released its earnings results on Tuesday, March 31st. The company reported ($0.42) earnings per share (EPS) for the quarter. The company had revenue of $35.77 million for the quarter. Valneva had a negative return on equity of 107.63% and a negative net margin of 88.87%. Sell-side analysts expect that Valneva will post -1 EPS for the current fiscal year.

Institutional Trading of Valneva

Several large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. acquired a new stake in shares of Valneva during the third quarter valued at about $124,000. XTX Topco Ltd acquired a new stake in shares of Valneva during the fourth quarter valued at about $94,000. Marex Group plc acquired a new stake in shares of Valneva during the second quarter valued at about $64,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Valneva during the fourth quarter valued at about $44,000. Finally, VSM Wealth Advisory LLC boosted its stake in shares of Valneva by 125.0% during the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after purchasing an additional 5,000 shares in the last quarter. 11.39% of the stock is owned by institutional investors and hedge funds.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.